Clinical Trial Update: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age [Phase 3]

View source ↗

Summary

This is a Phase 3 trial update for Viaskin Peanut in peanut-allergic children aged 4-7. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Allergy, Peanut | Phase 3 | Status: ACTIVE_NOT_RECRUITING